New combo therapy targets rare blood cancer in early trial
NCT ID NCT03805932
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find a safe dose and see if the combination can shrink or eliminate the cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
- New drug duo aims to tackle rare leukemia
- New registry aims to unlock secrets of rare leukemia
- Engineered immune cells take aim at stubborn blood cancers
- New combo aims to tame hairy cell leukemia with fewer side effects
- Engineered t cells take on tough leukemia and lymphoma